To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B
Latest Information Update: 20 Aug 2022
Price :
$35 *
At a glance
- Drugs GST-HG141 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Fujian Cosunter Pharmaceutical
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 06 Jun 2022 Status changed from recruiting to completed.
- 05 Jun 2022 Status changed from not yet recruiting to recruiting.